Naomi Birbach is an associate in Goodwin’s IP Litigation group. She joined the firm in 2013.
Ms. Birbach focuses her practice on intellectual property litigation in U.S. district courts and before the U.S. Patent and Trademark Office Patent Trial and Appeal Board (PTAB) in post-grant proceedings such as inter partes reviews (IPRs). She has worked on cases involving pharmaceuticals, electronic devices, and display systems. Ms. Birbach has particular expertise in generic drug litigation under the Hatch-Waxman Act.
Ms. Birbach is also an editor of the firm’s biosimilars blog, Big Molecule Watch, which provides resources and observations through Goodwin’s active watch of legal, business and regulatory developments related to biologics, biosimilars and the Biologics Price Competition and Innovation Act (BPCIA).